Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Mesothelioma: Pleural, Version 1.2024. Journal of the National Comprehensive Cancer Network : JNCCN Stevenson, J., Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., DeCamp, M., Desai, A., Dilling, T. J., Dowell, J., Durm, G. A., Garassino, M. C., Gettinger, S., Grotz, T. E., Gubens, M. A., Lackner, R. P., Lanuti, M., Lin, J., Loo, B. W., Lovly, C. M., Maldonado, F., Massarelli, E., Morgensztern, D., Mullikin, T. C., Ng, T., Otterson, G. A., Owen, D., Patel, S. P., Patil, T., Polanco, P. M., Riely, G. J., Riess, J., Shapiro, T. A., Singh, A. P., Tam, A., Tanvetyanon, T., Yanagawa, J., Yang, S. C., Yau, E., Gregory, K., Hang, L. 2024; 22 (2): 72-81

Abstract

Mesothelioma is a rare cancer that originates from the mesothelial surfaces of the pleura and other sites, and is estimated to occur in approximately 3,500 people in the United States annually. Pleural mesothelioma is the most common type and represents approximately 85% of these cases. The NCCN Guidelines for Mesothelioma: Pleural provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with pleural mesothelioma. These NCCN Guidelines Insights highlight significant updates to the NCCN Guidelines for Mesothelioma: Pleural, including revised guidance on disease classification and systemic therapy options.

View details for DOI 10.6004/jnccn.2024.0014

View details for PubMedID 38503043